<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04073706</url>
  </required_header>
  <id_info>
    <org_study_id>ENDO-3</org_study_id>
    <nct_id>NCT04073706</nct_id>
  </id_info>
  <brief_title>Sentinel Node Biopsy in Endometrial Cancer</brief_title>
  <acronym>ENDO-3</acronym>
  <official_title>A Phase III Randomised Clinical Trial Comparing Sentinel Node Biopsy With No Retroperitoneal Node Dissection in Apparent Early-Stage Endometrial Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Queensland Centre for Gynaecological Cancer</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The University of Queensland</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Queensland Centre for Gynaecological Cancer</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Endometrial cancer (EC) is the most common gynaecological cancer. Current treatment of EC
      typically includes removal of the uterus and to determine the extent of the disease (removal
      of fallopian tubes, ovaries &amp; if required a lymph node dissection (surgical staging)). While
      lymph node dissection may be valuable to guide the need for adjuvant treatment (chemo or
      radiotherapy) after surgery, it has been a topic of controversy for the last 30 years. In
      some patients it causes morbidity, specifically lymphoedema. This recently has been replaced
      with sentinel node biopsy (SNB). It requires an injection of a dye into the cervix with
      specific equipment &amp; surgical dissection of the lymph node in which the dye first becomes
      visible. Despite this promising proposition &amp; similar to a lymph node dissection, the value
      to patients, cost effectiveness &amp; potential harms (e.g. lymphedema) of SNB compared to
      no-node dissection in EC has never been established. Aim: determine the value of SNB for
      patients, the healthcare system and exclude detriment to patients using a randomised approach
      1:1. Outcome: Disease free survival is equivalent in patients undergoing a hysterectomy for
      EC having an SNB vs those having no lymph node dissection.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Hypothesis: The primary hypothesis is that disease-free survival in patients with SNB versus
      without retroperitoneal node dissection is equivalent. The secondary hypothesis is that SNB
      will not be cost effective and will cause detriment to patients (lymphoedema, morbidity, loss
      of quality of life).

      Aims: To determine the value of SNB for patients, the healthcare system and to exclude
      detriment to patients.

      Objectives:

      Primary: Compare disease-free survival at 4.5 years for participants randomised to receive
      hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to
      hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection.

      Secondary:

        -  Compare patterns of recurrence and overall survival between the groups

        -  Determine the cost-effectiveness of SNB

        -  Compare perioperative outcomes (duration of surgery, length of hospital stay,
           intraoperative blood loss, blood transfusion requirements) and the incidence of intra-
           and postoperative adverse events within 12 months from surgery between groups

        -  Compare quality of life at 12 months after surgery

        -  Compare lower limb lymphoedema at 12 months after surgery

        -  Compare the need for postoperative (adjuvant) treatments between groups

        -  Determine the impact of body composition and frailty on survival, quality of life,
           lymphoedema, peri-, intra- and postoperative outcomes

        -  Determine the value of follow-up strategies
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2020</start_date>
  <completion_date type="Anticipated">January 1, 2030</completion_date>
  <primary_completion_date type="Anticipated">January 1, 2030</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Disease Free Survival</measure>
    <time_frame>4.5 years after surgery</time_frame>
    <description>Compare disease-free survival for participants randomised to receive hysterectomy, bilateral salpingo-oophorectomy with SNB compared to participants randomised to hysterectomy, bilateral salpingo-oophorectomy without retroperitoneal node dissection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Patterns of Recurrence</measure>
    <time_frame>Over 4.5 years after surgery</time_frame>
    <description>Compare patterns of recurrence and overall survival (OS) between the groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cost Effectiveness using QALYs and EuroQoL-5D (EQ-5D) Questionnaire</measure>
    <time_frame>4.5 years after surgery</time_frame>
    <description>An assessment will be performed on the cost-effectiveness of TH + SNB relative to TH alone, calculated as the incremental cost per unit of improvement in functional outcome, measured in terms of the primary outcome. This will assess how much more money the proposed intervention will cost the health system and society, and whether this represents a sound investment in terms of the improvement in quality of life. We will also measure the quality-adjusted life years (QALYs) gained with the intervention and use this to undertake a cost-utility analysis. The QALY calculations will be based on health status measures for trial participants, with valuations of changes in health status and quality of life based on the EQ-5D</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes: Adverse Events</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare perioperative outcomes and the incidence of intra- and postoperative adverse events within 12 months from surgery between groups using Common Terminology Criteria for Adverse Events (CTCAE version 5)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes: Duration of Surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare the duration of Surgery between the two groups. This will be measured in hours and minutes (hh:mm)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes: Blood Loss during Surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare the blood loss between the two groups during surgery. This will be recorded in ml.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes: Blood Transfusion Requirements during Surgery</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare the blood transfusion requirements between the two groups. This will be recorded in units and recorded on the Surgery Form and the Concomitant Medication Form.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Perioperative Outcomes: Length of Hospital Stay</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare the length of hospital stay between the two groups. The duration will be measured in days. Date of surgery being day 0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of Life Questionnaires</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare quality of life between groups using Functional Assessment of Chronic Illness Therapy specifically for Endometrial Cancer (FACT-EN). The FACT-EN has been constructed to address relevant disease, treatment, or condition-related issues. It is intended to be as specific as necessary to capture the clinically-relevant problems associated with a given condition or symptom.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Lymphedema</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare lower limb lymphedema between groups</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adjuvant Treatment Requirements</measure>
    <time_frame>12 months after surgery</time_frame>
    <description>Compare the need for postoperative (adjuvant) treatments between groups and evaluate the impact of SNB on clinical decisions regarding adjuvant treatment. Any chemotherapy or radiation therapy required will be recorded on specific chemotherapy or radiation forms. Chemotherapy will be recorded in mg received and number of doses required including start/end dates. Radiation treatment received will be recorded as total dose of Gy and how many fractions, including start and end dates.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of body composition (sarcopenia) on surgical complications, recovery and overall survival</measure>
    <time_frame>4.5 years after surgery</time_frame>
    <description>Body mass measures are practical &amp; sensitive for predicting health risks &amp; outcomes. Sarcopenia is defined as loss of skeletal muscle mass &amp; strength. It's been found to be associated with procedure-related morbidity, survival in cancer patients and increased use of healthcare. The concurrent appearance of low muscle mass with high adiposity (sarcopenic obesity) is common in people with chronic diseases. The trial will determine the role sarcopenia has on participants pre-operatively (via CT images &amp; Bioimpedance Spectroscopy (BIS - if available at site) &amp; postoperatively using the BIS in regard to survival in gynaecological malignancies, if it is a predictive factor for treatment adverse events &amp; participants tolerability of treatment &amp; compare diagnostic methods to determine medical fitness for surgery. BIS sends non-detectable electrical currents, at a range of frequencies through the body allowing precise measurement &amp; analysis of impedance to currents by extracellular fluid</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Impact of frailty on surgical complications, recovery and overall survival</measure>
    <time_frame>4.5 years after surgery</time_frame>
    <description>It has been reported consistently that frailty has a significant impact on the occurrence of adverse postoperative outcomes. Therefore, measuring frailty is important to estimate risks, determine the best treatment options, and to aid diagnosis and care planning. Frailty will be measured prior to surgery suing the validated tool - Frailty Phenotype. This may determine the impact frailty has on survival, quality of life, lymphedema, peri-, intra- and postoperative outcomes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follow-Up Strategies</measure>
    <time_frame>4.5 years after surgery</time_frame>
    <description>Current institutional &amp; clinical guidelines suggest patients need to be seen at regular follow up visits. The risk of developing a recurrence is higher within the initial period after surgery &amp; the majority of recurrences develop within those first 3 years. Participants will ideally be seen 3 monthly for the first 3 years &amp; 6 monthly until 4.5 years. The objective of follow up is that local recurrences from endometrial cancer are potentially curable. It helps to diagnose local recurrences as early as possible so that they are amenable for curative or effective palliative management. We will compare these clinical findings to a symptom checklist that will be completed by participants every 3 months from surgery until 4.5 years. This records patient reported symptoms that may indicate a recurrence. Comparing these findings should determine effective follow up strategies for this group of patients.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">760</enrollment>
  <condition>Endometrial Cancer Stage I</condition>
  <condition>Sentinel Lymph Node</condition>
  <condition>Surgery</condition>
  <arm_group>
    <arm_group_label>TH BSO with SNB</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) with Sentinel Node Biopsy (SNB) using Indocyanine Green (ICG) (+/- omentectomy in high risk cell types)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>TH BSO without retroperitoneal node dissection</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Total Laparoscopic/Robotic Hysterectomy, Bilateral Salpingo-Oophorectomy (TH BSO) without retroperitoneal node dissection (+/- omentectomy in high risk cell types)</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TH BSO with SNB</intervention_name>
    <description>Removal of uterus, tubes and ovaries with a sentinel node biopsy. A tracer dye (ICG) is injected into the surroundings of the primary tumour, it is transported via local lymphatic channels towards the draining lymphatic basin, and the first node that the tracer reaches is called the &quot;sentinel node&quot;. These one or two nodes are thought to be first involved with cancer spread.</description>
    <arm_group_label>TH BSO with SNB</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>TH BSO without retroperitoneal node dissection</intervention_name>
    <description>Removal of uterus, tubes and ovaries without retroperitoneal node dissection</description>
    <arm_group_label>TH BSO without retroperitoneal node dissection</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Females, over 18 years, with histologically confirmed primary epithelial
             adenocarcinoma of the endometrium of any cell type or uterine carcinosarcoma (mixed
             malignant mullerian tumour);

          2. Clinically stage I disease (disease confined to body of uterus);

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1;

          4. Signed written informed consent;

          5. Participant must meet criteria for a laparoscopic or robotic surgical approach as
             determined by the treating physician (e.g. suitable for TH BSO, ability to tolerate
             reverse Trendelenberg position)

          6. All available clinical evidence (physical examination findings, or medical imaging
             such as CT, MRI or ultrasound) demonstrates no evidence of extrauterine disease

          7. Negative serum pregnancy test â‰¤ 30 days of surgery in pre-menopausal women and women &lt;
             2 years after the onset of menopause.

        Exclusion Criteria:

          1. Evidence of extrauterine disease (apparent involvement of cervix, vagina, parametria,
             adnexa, lymph nodes, bladder, bowel or distant sites) by clinical examination and/or
             through medical imaging.

          2. Enlarged retroperitoneal pelvic and/or aortic lymph nodes (&gt;1 cm) on medical imaging;

          3. Estimated life expectancy of less than 6 months;

          4. Patients who have absolute contraindications for adjuvant radiotherapy and/or
             chemotherapy;

          5. Patients who have previously received chemotherapy and/or radiation treatment to the
             pelvis

          6. Serious concomitant systemic disorders incompatible with the study (at the discretion
             of the investigator);

          7. Patient compliance and geographic proximity that do not allow adequate follow-up;

          8. Patients with allergy to Indocyanine Green (ICG)

          9. Patients who have had previous retroperitoneal surgery

         10. Patients who require a retroperitoneal (pelvic +/- para-aortic) lymph node dissection
             (lymphadenectomy)

         11. Other prior malignancies &lt;5 years before inclusion, except successfully treated basal
             cell or squamous cell skin cancer, or ductal carcinoma of the breast.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Obermiar, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Director, Queensland Centre for Gynaecological Cancer Research</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vanessa Behan, BSN</last_name>
    <phone>+61 7 3346 5590</phone>
    <email>endo3trial@health.qld.gov.au</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Trudi Cattley</last_name>
    <phone>+61 7 3346 5063</phone>
    <email>trudi.cattley@health.qld.gov.au</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>John Hunter Hospital</name>
      <address>
        <city>Newcastle</city>
        <state>New South Wales</state>
        <zip>2305</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Ken Jaaback, MD</last_name>
      <phone>+ 61 2 4989 6896</phone>
      <email>kenneth.jaaback@health.nsw.gov.au</email>
    </contact>
    <investigator>
      <last_name>Ken Jaaback, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Townsville Hospital</name>
      <address>
        <city>Douglas</city>
        <state>Queensland</state>
        <zip>4814</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Behan, BSN</last_name>
      <phone>+ 61 7 3346 5590</phone>
      <email>endo3trial@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Greet Hoet, MD</last_name>
      <phone>+ 61 7 4433 3622</phone>
      <email>Greet.Hoet@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Greet Hoet, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Brisbane and Women's Hospital</name>
      <address>
        <city>Herston</city>
        <state>Queensland</state>
        <zip>4029</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Behan, BSN</last_name>
      <phone>+61 7 3346 5590</phone>
      <email>endo3trial@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+61 7 3346 5063</phone>
      <email>trudi.cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Andreas Obermair, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mater Hospital</name>
      <address>
        <city>South Brisbane</city>
        <state>Queensland</state>
        <zip>4101</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Behan, BSN</last_name>
      <phone>+61 7 3346 5590</phone>
      <email>endo3trial@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+ 61 7 3346 5063</phone>
      <email>trudi.cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Lewis Perrin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Gold Coast University Hospital</name>
      <address>
        <city>Southport</city>
        <state>Queensland</state>
        <zip>4215</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Vanessa Behan, BSN</last_name>
      <phone>+61 7 3346 5590</phone>
      <email>endo3trial@health.qld.gov.au</email>
    </contact>
    <contact_backup>
      <last_name>Trudi Cattley</last_name>
      <phone>+61 7 3346 5063</phone>
      <email>trudi.cattley@health.qld.gov.au</email>
    </contact_backup>
    <investigator>
      <last_name>Marcelo Nascimento, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Royal Women's Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <zip>3052</zip>
        <country>Australia</country>
      </address>
    </facility>
    <contact>
      <last_name>Julie Silvers</last_name>
      <email>Julie.Silvers@thewomens.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Orla McNally, MD</last_name>
      <email>Orla.McNally@thewomens.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Orla McNally, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 26, 2019</study_first_submitted>
  <study_first_submitted_qc>August 27, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 29, 2019</study_first_posted>
  <last_update_submitted>March 2, 2020</last_update_submitted>
  <last_update_submitted_qc>March 2, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>uterine cancer</keyword>
  <keyword>sentinel node biopsy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Endometrial Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

